Blood testing to classify patients was recently described using plasma tau protein 217, potentially accurately stratifying and detecting Alzheimer’s disease in a cost-effective way (Brum et al., 2023). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.